AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Leerink Partners Raises IDXX Price Target to $600, Maintains 'Outperform' Rating
ByAinvest
Saturday, Jul 19, 2025 5:36 am ET1min read
Leerink Partners analyst Daniel Clark raises IDEXX Laboratories' (IDXX) price target to $600 from $580, a 3.45% increase, while reaffirming his "Outperform" rating. The average analyst target price is $531.30, with a high estimate of $625.00 and a low estimate of $389.92, indicating a potential 2.43% upside. GuruFocus estimates a one-year GF Value of $571.11, suggesting a 10.1% upside from the current price.
Leerink Partners analyst Daniel Clark has raised the price target for IDEXX Laboratories (IDXX) to $600 from $580, representing a 3.45% increase. The analyst maintains an "Outperform" rating on the stock. This adjustment comes after thorough channel checks and insights from a semiannual survey conducted with veterinarians, reflecting continued confidence in IDEXX's strategic positioning and growth prospects [1].The updated price target of $600 aligns with the average one-year target price of $531.30, as forecasted by 13 analysts. The high estimate of $625.00 and the low estimate of $389.92 suggest a potential upside of 2.43% from the current price of $518.71 [2].
GuruFocus estimates a one-year GF Value of $571.11 for IDEXX Laboratories, suggesting a 10.1% upside from the current price of $518.71. This estimate is based on historical multiples, past business growth, and future performance estimates [2].
IDEXX Laboratories reported a 5% organic revenue growth in Q1 2025, driven by strong performance in CAG Diagnostics and veterinary software. The company also achieved a 9% expansion in its premium instrument install base and reported a 10% organic growth in IDEXX VetLab consumable revenues. However, the company faced challenges such as a 2.6% decline in US clinical visits and a 13% decline in CAG premium instrument placements compared to high prior year levels [2].
IDEXX Laboratories continues to position itself strongly in the veterinary healthcare sector, with a healthy balance sheet and a positive outlook for 2025. The company's 2025 revenue guidance is $4,095 million to $4,210 million, with a 6% to 9% organic growth outlook, and the EPS guidance is $11.93 to $12.43 per share, with an 8% to 12% comparable EPS growth [2].
References:
[1] https://www.gurufocus.com/news/2985882/idxx-analyst-leerink-partners-raises-price-target-to-600-idxx-stock-news
[2] https://www.gurufocus.com/news/2983331/idexx-laboratories-idxx-sees-raised-price-target-from-leerink-analyst-idxx-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet